🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 32 of 173

  1. US 11274294

    TAL effector-mediated DNA modification

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11275080

    Methods for stratifying non-responders to therapies that block PD1/PDL1 axis

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11267832

    Mn(II)-based sensors to detect zinc in vivo with MRI

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11267822

    BET bromodomain protein degraders with cleavable linkers

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11266488

    Tissue repair fiber membrane, preparation method and application thereof, and tissue repair product

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11267859

    GM-CSF mimetics and methods of making and using same

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11260083

    Compositions and methods for treating and preventing graft versus host disease

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11260058

    Compositions and method of treating cancer

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11261432

    Method and composition for inducing human pluripotent stem cells

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11261237

    Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11260089

    Products of manufacture comprising bacteriophages

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11260073

    Compounds and methods for modulating C90RF72

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11260070

    Methods of treating feline coronavirus infections

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11261461

    Methods and compositions for selective generation of dopaminergic precursors

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11260092

    Fungal immunogens and related materials and methods

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11261231

    Methods for inhibiting HIV or HCV infection by administering TIM-3 binding inhibitors

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11261471

    Methods and compositions for making vault particles in yeast

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11254640

    N-substituted indoles and other heterocycles for treating brain disorders

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11253604

    Conjugate of methotrexate and peptide

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11254713

    Method to enhance immunogenicity of live typhoid vaccines and carriers

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11253546

    Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11253483

    Protease assisted native-protein delivery approach (PANDA)

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11253506

    Compounds, compositions and methods for preventing and/or treating chlorine inhalation toxicity and/or injury

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11253522

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11255865

    Immunoassay for human erythroferrone

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11247968

    Lipocationic dendrimers and uses thereof

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11248022

    Glypican-3 peptide reagents and methods

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11248213

    Platform for generating safe cell therapeutics

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11247985

    Phenyl indole allosteric inhibitors of P97 ATPase

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11246940

    Peptides whose uptake in cells is controllable

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11246937

    One-step processing of hydrogels for mechanically robust and chemically desired features

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11246961

    Engineered scaffolds for vascularized tissue repair

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11247974

    Small molecules that enable cartilage rejuvenation

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11248270

    Methods and kits to identify Klebsiella strains

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11241460

    Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11241380

    Porous photonic crystals for drug delivery to the eye

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11242543

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11241458

    Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11241483

    Methods of treating mild brain injury

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11242510

    Mammalian cells devoid of lactate dehydrogenase activity

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11241394

    Treating vasculature related diseases or disorders using nanoparticles

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11242533

    RNA-nanostructured double robots and methods of use thereof

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11234992

    Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11235066

    Micelles and methods

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11236402

    Adeno-associated virus virions with variant capsid

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11236360

    Adeno-associated viruses engineered for selectable tropism

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11236301

    Thin film cell encapsulation devices

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11236044

    Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.